Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment

Abstract Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD usi...

Full description

Bibliographic Details
Main Authors: Jehun Kim, Taeyun Kim, Tae Won Jang, Hee Kang, Mi Hyun Kim, Seong Hoon Yoon, Choon‐Hee Son, Hyun‐Kyung Lee, Hyun‐Kuk Kim, Shin Yup Lee, Kyeong Choel Shin, Ji‐Yeon Han, Eun‐Ju Kang
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Thoracic Cancer
Subjects:
hyperprogression
immune checkpoint inhibitor
non‐small cell lung cancer
volumetry
Online Access:https://doi.org/10.1111/1759-7714.14539

Internet

https://doi.org/10.1111/1759-7714.14539

Similar Items